Impromidine

Impromidine is a histamine H2 receptor antagonist that was studied for the treatment of peptic ulcer disease. It was never marketed.

History

Impromidine was first synthesized in the 1970s by Smith, Kline & French (now part of GlaxoSmithKline), as part of a program to develop H2 receptor antagonists. The compound was found to be a potent and selective H2 antagonist, but it was not developed further due to its poor oral bioavailability.

Pharmacology

Impromidine is a potent and selective antagonist of the histamine H2 receptor. It has been shown to inhibit gastric acid secretion in animal models, and it has been studied in clinical trials for the treatment of peptic ulcer disease.

Clinical trials

In clinical trials, impromidine was found to be effective in reducing gastric acid secretion and promoting the healing of peptic ulcers. However, the drug was not developed further due to its poor oral bioavailability.

See also

• Histamine H2 receptor
• Peptic ulcer disease
• Histamine H2-receptor antagonists

Impromidine Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski